4 Healthcare Stock Stories For Monday Investment Wellness

Boston Scientific Corporation (NYSE:BSX): Current price $7.54

The corporation has received approval by the FDA and is commencing a limited intro of the Precision Spectra Spinal Cord Stimulator System. The system is the world’s first and sole SCS system with Illumina 3D software and 32 contacts, and is created to give improved pain relief to a wide array of patients who suffer from chronic pain.  Boston Scientific will debut the system at the annual meeting of the American Academy of Pain Medicine in Fort Lauderdale.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BSX

Johnson & Johnson (NYSE:JNJ): Current Price $82.43

In a report, Jefferies Group has placed a $85 price target on Johnson & Johnson, and it currently has a a Hold on the stock. A Jefferies analyst commented that “we remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the U.S. is AbbVie, with Novartis being our most preferred name in Europe. Sanofi , Roche, and Pfizer  remain high conviction Buy ratings. We point to Eli Lilly  and GlaxoSmithKline as least preferred names.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

JNJ

Becton, Dickinson and Company (NYSE: BDX): Current price $95.50

Becton’s BD Medical arm has announced the commercial debut of a new passive needle guard tech, BD UltraSafe PLU. The guard has attained 510-K clearance as an anti-needlestick safety device. This product, along with offering needlestick safety in an easy-to-use one-handed device, is improved with ergonomic features designed to facilitate comfort and support for both healthcare providers and patients. What is more, this safety device is designed to meet increasingly complex biotechnology drug requirements, including higher viscosity.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BDX

Abbott Laboratories (NASDAQ:ABT): Current price $36.57

Abbott is recalling its FreeStyle InsuLinx Blood Glucose Meters following the discovery that they display and store incorrect test results for dangerously high blood sugar levels. The firm  says that the meters will display and store readings for blood glucose levels of 1,024 milligrams per deciliter or higher at much lower levels, which is an extremely high and rare level that requires immediate medical attention. Moreover, the inaccurate readings could cause a delay in identifying the problem or incorrect treatment.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ABT

Investing Insights: Is Merck Overvalued?

More from The Cheat Sheet